Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06203119
Status:
RECRUITING
Last Update Posted:
2024-01-12
First Post:
2024-01-02
Brief Title:
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label positron emission tomographycomputed tomography PETCT study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer The visual and semiquantitative methods will be used to assess the PETCT images
Detailed Description:
ACE is expressed in triple-negative breast cancer cells This project develops new type of 68GA-labeled DOTA-BPP leveraging the inherent strengths of this nuclear medicine discipline promoted the formulation of the production of this drug To obtain 68Ga-DOTA-BPP injection that can be used in preclinical studies and meets clinical standards Join a group In clinical patients 68Ga-DOTA-BPP PETCT imaging of patients with ACE-positive TNBC was performed and ACE was obtained To provide evidence for patient screening and efficacy evaluation before targeted therapy with high expression of TNBC and preliminatively evaluate the level of ACE against high level of ACE The effect of tumor development can provide a practical basis for the establishment of ACE-targeted PET imaging platform
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None